| Bioactivity | TRAM-39 is a selective blocker of intermediate conductance Ca2+-activated K+ (IKCa) channels. TRAM-39 inhibits KCa3.1 channel with an IC50 value of 60 nM. TRAM-39 can be used for the research of ataxia, epilepsy, memory disorders, schizophrenia and Parkinson’s disease[1][2][3][4]. |
| Target | IC50: 60 nM (KCa3.1 channel) |
| Invitro | TRAM-39 (1 μM) reduces the peak amplitude of gKCa2 in sympathetic LAH neurons (mean percentage change 56%) in BAE cells[2].TRAM-39 (200 nM) diminishes lipopolysaccharide (LPS)-induced cryptdin release from paneth cells[3]. |
| In Vivo | TRAM-39 (1 μM; adds to the perfusate) fully blocks all IKCa channels in multicellular preparations[1]. |
| Name | TRAM-39 |
| CAS | 197525-99-8 |
| Formula | C20H14ClN |
| Molar Mass | 303.78 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Davies PJ, et al. Different types of potassium channels underlie the long afterhyperpolarization in guinea-pig sympathetic and enteric neurons. Auton Neurosci. 2006 Jan 30;124(1-2):26-30. [2]. Burnham MP, et al. Impaired small-conductance Ca2+-activated K+ channel-dependent EDHF responses in Type II diabetic ZDF rats. Br J Pharmacol. 2006 Jun;148(4):434-41. [3]. Ayabe T, et al. Modulation of mouse Paneth cell alpha-defensin secretion by mIKCa1, a Ca2+-activated, intermediate conductance potassium channel. J Biol Chem. 2002 Feb 1;277(5):3793-800. [4]. Wulff H, et al. Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. Curr Med Chem. 2007;14(13):1437-57. |